Filing summary
Identity and period: The supplied filing is Stellar Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2015, covering three- and nine-month comparisons. This does not match the request metadata identifying Edesa Biotech, Inc.; verify the issuer before relying on this summary. Amounts are in U.S. dollars.
Business context and financial position
Stellar aquacultures, researches, manufactures and commercializes keyhole limpet hemocyanin (KLH) for biotechnology, pharmaceutical, academic and clinical research customers. The company reported 79,546,650 common shares outstanding as of August 1, 2015.
- At June 30, 2015, cash and cash equivalents were $10.16 million; current assets were $10.73 million; total assets were $11.21 million.
- Working capital was $8.94 million, including a $1.24 million current warrant liability. Total liabilities were $1.78 million, principally warrant liability and operating payables; the filing reports no conventional borrowings.
- Nine-month operating cash use was $3.50 million. Investing activities provided $216,286, financing provided $28,719, and cash declined $3.61 million to $10.16 million.
- Gross or operating margins are not clearly presented; the filing reports production costs and other expenses separately.
Results and comparison
- Nine months: Revenue increased to $558,036 from $245,734. Product sales rose to $408,036 from $70,994; contract services revenue was $150,000 versus $147,000; grant revenue was zero versus $27,740.
- Nine-month expenses declined to $3.95 million from $4.65 million. R&D fell to $830,115 from $1.82 million as the company shifted resources from internal research and contract research organizations toward manufacturing. Production and aquaculture costs increased to $661,644 from $442,820, alongside higher sales activity.
- Nine-month net loss narrowed to $1.31 million ($0.02 per basic share) from $3.60 million ($0.05 loss per share). The improvement was materially affected by a noncash warrant fair-value gain of $2.46 million, versus $834,000 in the prior period.
- Three months: Revenue was $157,748 versus $72,538; net income was $463,986 ($0.01 per basic share) versus $3.41 million ($0.04 per basic share). The lower quarterly income mainly reflected a smaller noncash warrant fair-value gain: $1.25 million versus $4.53 million.
- Cash fell from $13.77 million at September 30, 2014. The company attributed $356,207 of the nine-month cash decline to exchange-rate movements. Foreign-exchange loss for the period was $391,190.
Outlook, risks and notable items
- Management believed available resources were sufficient for at least 12 months at the current activity level, including contractual obligations and anticipated R&D. It also expected continued losses and said additional capital might be needed; future financing availability and acceptable terms were not assured.
- Revenue was described as volatile during market development. Three customers accounted for approximately 67% of nine-month product sales and contract-services revenue; one customer represented approximately 99% of accounts receivable at June 30.
- Contractual obligations totaled approximately $858,000: $681,000 in operating leases and $177,000 in purchase obligations. The company extended facility leases and leased undeveloped land in Baja California, with the first two years’ rent prepaid.
- A July 2015 collaboration with Ostiones Guerrero in Baja California contemplated assessing a potential additional aquaculture and KLH production site over three years; development depends on site suitability and entails company-funded improvements.
- The C. difficile technology license includes potential development and financing milestones of up to $6.02 million and contingent sales milestones totaling $57.03 million, plus royalties and certain patent costs. No milestones were met in the reported nine months; future achievement is uncertain.
- The filing reported no material changes to previously disclosed risk factors, no material legal proceedings outside the ordinary course, and effective disclosure controls as of June 30, 2015.
Most important facts to verify
- Confirm the filing belongs to Stellar Biotechnologies, not Edesa Biotech, and that June 30, 2015 is the intended reporting period.
- Assess the sustainability of product-sales growth and customer concentration, including the dependence of receivables on one customer.
- Separate operating performance from the substantial noncash warrant remeasurement gains when evaluating reported earnings.
- Review cash runway, projected operating cash use, lease and purchase commitments, and potential financing requirements.
- Verify progress and costs for the Baja California site, the Ostiones collaboration, and any milestones or obligations under the C. difficile license.